How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,838 results for

Patch Delivered Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600

2019 Effective Health Care Program (AHRQ)

2. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

3. Patch Delivered Medication

Delivered Medication Aka: Patch Delivered Medication , Transdermal Drug , Medication Patch From Related Chapters II. Precautions is heat sensitive Increases absorption and decreases duration Affected by fever, , heating pads, saunas Could dangerously increase levels (e.g. ) Avoid cutting patches unless specifically allowed es with evenly distributed medication may be cut (e.g. ) Avoid cutting patches with drug reservoir (e.g. , CQ) Avoid cutting patches for which exact dosing must be maintained (e.g (...) Patch Delivered Medication Patch Delivered Medication Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Patch Delivered Medication Patch

2018 FP Notebook

4. Comparative-Effectiveness of Group-Delivered Acceptance and Commitment Therapy vs. Cognitive Behavioral Therapy for Smoking Cessation: A Randomized Controlled Trial. (Abstract)

Comparative-Effectiveness of Group-Delivered Acceptance and Commitment Therapy vs. Cognitive Behavioral Therapy for Smoking Cessation: A Randomized Controlled Trial. Preliminary trial data suggests group-delivered Acceptance and Commitment Therapy (ACT) might be effective for smoking cessation. If so, this could offer a viable alternative to mainstream behavioral therapies, such as those grounded in Cognitive Behavioral Therapy (CBT). The goal of the current study was to compare (...) the effectiveness of group-delivered ACT versus group-delivered CBT in a rigorous randomized trial design with long term follow-up.Participants (n = 450) were recruited from the Kaiser Permanente Washington health care system and randomized to either ACT-based group counseling or an attention-matched CBT-based group program. All were prescribed an 8-week course of nicotine patches. The primary outcome was self-reported 30-day point prevalence abstinence (PPA) at 12 months post-randomization assessed

2018 Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco Controlled trial quality: uncertain

5. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Full Text available with Trip Pro

Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Background: Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequately controlled on basal insulin, initiating and managing mealtime insulin (...) , experience ratings at week 24, and device preferences at week 48 significantly favored the patch. Most health care providers preferred patch for mealtime insulin. Conclusions: Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider experience and preference for the patch.

2019 Diabetes technology & therapeutics Controlled trial quality: uncertain

6. Horizon scanning: what's next for medical and health research?

, such as personalised nutritional guidance or prompts for getting a flu jab. ? Other smart devices, based on AI technology, whose transformative potential was predicted to include: o Retinal scans to diagnose diabetes/hypertension more accurately o Screen-writing challenges to detect signs of Parkinson’s disease o Nano-devices that detect enzymes, for example to diagnose fatty liver disease o Skin patches that analyse vitamin deficiencies o Drugs with in-built sensors that collect data on drug action, efficacy (...) the scale of a health issue, to support health economic modelling and to deliver interventions. ? Repurposing data from online searches or social media was expected to identify and track infectious disease outbreaks and create targeted adverts with NHS-certified advice to treat and prevent further infection. Drug development ? Automated AI-based interfaces and processing using algorithms trained on large datasets will assist researchers to manage and interpret data for drug development, according

2019 Academy of Medical Sciences

7. Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery Full Text available with Trip Pro

Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery The aim of the study was to develop a reservoir-type transdermal patch for a controlled delivery of dexibuprofen and to evaluate its in vivo anti-inflammatory activity in Albino Wistar rats. In order to develop these patches, six formulations of dexibuprofen microemulsion comprising ethyl oleate, Tween 80: PG (2 : 1), and water were prepared by simplex lattice (...) design and characterized. The reservoir compartment was filled with these microemulsions and in vitro release and skin permeation were assessed. The optimized patch was obtained on the basis of the responses: Q24 and flux. The impact of drug loading, surface area, membrane thickness, adhesive, and agitation speed on drug release and permeation was also studied. The skin sensitivity reaction and in vivo anti-inflammatory activity of optimized patch were evaluated. Stability study at three different

2017 BioMed research international

8. Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

, as well as structural abnormalities, making it possible to deliver novel drugs free from cardiac liabilities and guide personalized therapy. This article briefly reviews the challenges of cardio-oncology, the strengths and limitations of using human induced pluripotent stem cell–derived cardiomyocytes to represent clinical findings in the nonclinical research space, and future directions for their further use. In the United States and Europe, cancer is the second leading cause of death and morbidity (...) of cultured hiPSC-CMs to test for cardiotoxicity with novel chimeric antigen receptor T cell–based therapies. As with all in vitro cell-based assay, challenges encountered with testing include delivering the drug at the specified (targeted) concentration, drug distribution within the test chamber, time course of exposure, presence (or absence) of metabolites that may be present in vivo, and extracellular accumulation of cellular products arising from the drug response. Human iPSC-CM–Derived In Vitro

2019 American Heart Association

9. A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity

A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03629041 Recruitment Status : Completed First Posted : August 14, 2018 Last Update Posted : September 20, 2018 Sponsor: Innoture Ltd

2018 Clinical Trials

10. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) and the evidentiary basis for such recommendations. This publication is intended as a living document to be updated periodically with consideration of new evidence. From the *Western Reserve Hospital, Cuyahoga Falls, OH; †Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL; ‡Pain Diagnostics and Interventional Care, Pittsburgh, PA; §Department of Anesthesiology, Rush University Medical Center, Chicago, IL; ∥Valencia University Medical School and Department

2018 American Society of Regional Anesthesia and Pain Medicine

11. Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis

of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis Study Start Date : December 2016 Estimated Primary Completion Date : March 2018 Estimated Study Completion Date : March 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment No Intervention: Non-treatment Control Control arm will not have any intervention Experimental: Luma Light System The experimental arm (...) Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

12. Chronic pain disorder medical treatment guideline.

of habit-forming potential, withdrawal symptoms, and sedating side effects. Flurazepam has an active metabolite with a very long half-life, resulting in drug accumulation and next-day somnolence. These medications are not recommended for use in the working populations. Evidence Statements Regarding Hypnotics and Sedatives Some Evidence Zolpidem does not appreciably enhance the effectiveness of cognitive behavioral therapy (Design: Randomized clinical trial ). Nonsteroidal Anti-Inflammatory Drugs (...) of individual and/or group patient education as a means of facilitating self-management of symptoms Psychological or psychosocial screening should be performed on all chronic pain patients. Acupuncture Acupuncture is recommended for subacute or chronic pain patients who are trying to increase function and/or decrease medication usage and have an expressed interest in this modality. It is also recommended for subacute or acute pain for patients who cannot tolerate nonsteroidal anti-inflammatory drugs (NSAIDs

2017 National Guideline Clearinghouse (partial archive)

13. Population pharmacokinetic model of transdermal nicotine delivered from a matrix‐type patch Full Text available with Trip Pro

Population pharmacokinetic model of transdermal nicotine delivered from a matrix‐type patch Nicotine addiction is an issue faced by millions of individuals worldwide. As a result, nicotine replacement therapies, such as transdermal nicotine patches, have become widely distributed and used. While the pharmacokinetics of transdermal nicotine have been extensively described using noncompartmental methods, there are few data available describing the between-subject variability in transdermal (...) and disposition of transdermal nicotine and its metabolism to cotinine and the pharmacokinetic variability between individuals who were administered the patch.© 2017 The British Pharmacological Society.

2017 British journal of clinical pharmacology

14. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. (Abstract)

Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. Pharmacokinetic (PK) interactions between the cytochrome P450 3A4 (CYP3A4) pathway and transdermally administered ethinyl estradiol (EE) and gestodene (GSD) were investigated. This paper reports the findings of three open-label, intra-individual, one-way crossover, Phase I trials. In two studies, women used (...) a novel contraceptive patch for 3 weeks during two 4-week study periods; in the second period, the CYP3A4 inhibitors erythromycin (Study 1) or ketoconazole (Study 2) were administered concurrently. In a third study, women received single doses of the CYP3A4 model substrate midazolam, alone and after 3 weeks of concurrent patch application. In each period, the EE/GSD patch (delivering low EE and GSD doses resulting in the same systemic exposure as a combined oral contraceptive containing 0.02 mg EE

2015 European journal of drug metabolism and pharmacokinetics Controlled trial quality: uncertain

15. British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy

Protocols for delivery of photodynamic therapy A successful PDT outcome requires the optimization of apply- ing the appropriate prodrug, drug or photosensitizer, light parameters and oxygen, thereby achieving the mechanism of action intended. The resultant photodynamic reaction at the target cell produces the therapeutic result. PDT utilizes the higher selectivity of the photosensitizer for the target tissue compared with healthy tissue. The topically applied photosen- sitizer prodrugs are converted (...) ; 159:1245–66. 7Ga al M, Otrosinka S, Balt as E et al. Photodynamic therapy of non- melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid. Acta Derm Venereol 2012; 92:173–5. 8 Hauschild A, Stock?eth E, Popp G et al. Optimization of photody- namic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160:1066–74. 9 Dirschka T, Radny P, Dominicus R et al. Ef

2019 British Association of Dermatologists

16. Topical Photodynamic therapy

Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence. Keywords: 5-aminolaevulinic acid, dermatology, guidelines, methyl aminolaevulinate, non- melanoma skin cancer, topical photodynamic therapy. 1. Introduction Photodynamic therapy (PDT) involves the activation of a photosensitizing drug by visible light to produce reactive oxygen species within target cells, resulting in their destruction with additional immune-modulatory effects (...) Pharmaceuticals, USA), is approved in N. America and certain other countries for AK, in a protocol that uses blue light. Many original studies of topical PDT used non-standardized preparations of ALA made in hospital pharmacies, so direct comparison of early studies may not be valid. Topical PDT is approved for the treatment of certain non-melanoma skin cancers (NMSC) in the immune-competent, used both as lesional or area/field-therapy, and has the potential to delay/reduce the development of new AK, although

2019 European Dermatology Forum

17. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Full Text available with Trip Pro

and electrolyte balance, minimizing insensible water losses, and preventing infection. Given the immune mechanism of action of these medicines, use of immune suppression, such as with systemic corticosteroids, is warranted and should be offered, though the use of systemic corticosteroids has been more controversial for the treatment of SJS/TEN, in general. For DRESS/DIHS, high-dose and usually prolonged courses of systemic corticosteroids is first-line therapy following cessation of the offending drug (...) of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA. Abstract Section: Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology

2018 American Society of Clinical Oncology Guidelines

18. Nicotine replacement therapy for smoking cessation: nicotine patch

Nicotine replacement therapy for smoking cessation: nicotine patch Nicotine replacement therapy for smoking cessation: nicotine patch Nicotine replacement therapy for smoking cessation: nicotine patch Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nicotine replacement therapy for smoking cessation: nicotine patch. Lansdale: HAYES, Inc.. Directory Publication (...) patch; additional formulations, including a nicotine pouch, nicotine water, sublingual tablets, nicotine lollipops, and nicotine mouth spray, are available in countries outside of the United States (not FDA approved). The nicotine patch is worn on the skin throughout the day or day and night and delivers a steady dose of nicotine transdermally. Unlike other NRT formulations, the nicotine patch does not allow for direct dose control by its user. Final publication URL The report may be purchased from

2011 Health Technology Assessment (HTA) Database.

19. Patch Delivered Medication

Delivered Medication Aka: Patch Delivered Medication , Transdermal Drug , Medication Patch From Related Chapters II. Precautions is heat sensitive Increases absorption and decreases duration Affected by fever, , heating pads, saunas Could dangerously increase levels (e.g. ) Avoid cutting patches unless specifically allowed es with evenly distributed medication may be cut (e.g. ) Avoid cutting patches with drug reservoir (e.g. , CQ) Avoid cutting patches for which exact dosing must be maintained (e.g (...) Patch Delivered Medication Patch Delivered Medication Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Patch Delivered Medication Patch

2015 FP Notebook

20. Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease Full Text available with Trip Pro

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease Galantamine hydrobromide (GH) is an effective drug for Alzheimer's disease. It is currently delivered via the oral route, and this might cause nausea, vomiting, and gastrointestinal disturbance. In the present work, GH was formulated in a gel-type drug reservoir and then optimized by using response surface methodology (RSM) based on central composite design (...) amount at 8 hours of 17.80 mg·cm(-2) and the predicted permeation flux of 2.27 mg·cm(-2)/h. These predicted values have good agreement to actual cumulative drug release amount at 8 hours (16.93±0.08 mg·cm(-2)) and actual permeation flux (2.32±0.02 mg·cm(-2)/h). This optimized reservoir formulation was then fabricated in the transdermal patch system. This patch system has moderate pH, high drug content, and controlled drug-release pattern. Thus, this patch system has the potential to be used

2015 International journal of nanomedicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>